Esther von Stebut

Head of department

University Hospital
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Esther von Stebut is the Head of the Department at University Hospital Cologne, Germany. Her research primarily focuses on the quality of life impairments in patients with chronic skin conditions, as evidenced by her recent article on Hidradenitis Suppurativa. She has contributed to the understanding of patient perspectives and outcomes in dermatological health.

Articles (5)

Year:

2026

Background Cutaneous non‐tuberculous mycobacterial infections (NTM) remain a diagnostic and therapeutic challenge. The aim of this study was to characterize cutaneous NTM infections in Germany over a 24‐year‐period. Patients and Methods 73 patients with cutaneous NTM infections diagnosed at 17 different German University Hospitals from 2000–2011 and 21 patients treated at the Department of Dermatology of the University Hospital Cologne, from 2010–2024. Retrospective analysis of patient, demographic, clinical information, and data on different diagnostic workups and therapeutic approaches/responses. Results Together, 94 cases were analyzed (71% males, mean age 50, > 75% immunocompetent). Exposure to fish tanks was the dominant risk factor. Pathogen detection by nucleic acid amplification test and/or culture was successful in 76%. The most common pathogen was Mycobacterium (M.) marinum (> 65%), followed by M. abscessus/chelonae . Immunosuppression was associated with NTM other than M. marinum . Over 90% were treated with oral antibiotics, in more than 50% with a single antibiotic (mostly clarithromycin). The most common combination was clarithromycin plus rifampicin. The mean duration of therapy was more than 4 months. Complications, adverse events, and relapses were rare. Conclusions Our findings highlight that there is a need for standardized diagnostic procedures‐ and therapeutic recommendations for cutaneous NTM infections.

Year:

2025

Treatment against leishmaniasis is associated with severe side effects, high costs, and parasitic resistance. Preclinical models such as humanised mice would aid therapeutic improvement or the development of a vaccine. We developed a model in which human skin transplants on immunodeficient mice are infected with Leishmania major . Parasite inoculation of the skin transplant led to a robust infection with increasing numbers of parasites in the skin and visceral organs. In addition, intraperitoneally co‐administered allogeneic peripheral blood mononuclear cells (PBMCs) were strongly recruited to skin lesions, with ≥ 65% of the cells being positive for anti‐human CD45; we identified ~20% CD4 + and ~50% CD8 + human T cells. The number of skin‐resident macrophages or dendritic cells was unaltered compared to healthy skin prior to transplantation, and PBMC administration did not alter their numbers. Together, we show that parasitic infection provides a strong inflammatory signal that leads to recruitment of T cells into skin transplants. The presence of antigen‐presenting cells in the transplants—as an important prerequisite for proper APC‐T‐cell interaction—recreates a fully human skin microenvironment that allows for stroma/immune cell interactions upon infection. This model may be of high interest to researchers interested in translating skin research questions into the human system in vivo.

Year:

2025

The deubiquitinating enzyme CYLD negatively regulates NF-κB signaling by removing activating ubiquitin chains from several members of the NF-κB pathway. Thereby, CYLD is critical for the maintenance and differentiation of various immune cells. Despite the importance of the NF-κB pathway in microglia regulation, the role of CYLD in microglia has not been investigated so far. In this study, we investigated whether CYLD in microglia can protect against neuroinflammation using a newly generated conditional mouse strain (Rosa26-Cyld-tdTomato) that allows cell type-specific CYLD overexpression. Here, we show that overexpression of CYLD in microglia did not alter microglia numbers or microglia morphology in different brain regions. Additionally, CYLD overexpression did not modify the microglial response to LPS-induced neuroinflammation or the disease severity in experimental autoimmune encephalomyelitis (EAE). Finally, also immune cell infiltration into the CNS during EAE and under steady state conditions remained unaffected by microglial CYLD overexpression. Our findings suggest that CYLD overexpression does not alter microglial function, and thus does not represent a viable therapeutic strategy in neuroinflammatory conditions. This study highlights the complexity of ubiquitin-mediated signaling in neuroinflammation and the need for cell-type-specific investigations. The Rosa26-Cyld-tdTomato mouse model offers a valuable tool for studying CYLD’s role across various tissues and cell types. Key messages Novel mouse strain for cell type-specific overexpression of the deubiquitinating enzyme CYLD. CYLD overexpression in microglia did not alter microglia numbers or morphology in the steady state. CYLD overexpression in microglia did not protect mice from LPS-induced neuroinflammation or EAE. CYLD overexpression in microglia did not influence their gene expression during neuroinflammation.

Year:

2024

Year:

2021

Collaborators (5)

Ari Waisman

Institue Director and full Professor

University Medical Center of the Johannes Gutenberg University Mainz

GERMANY
View details

William Damsky

Associate Professor of Dermatology

Yale University

UNITED STATES
View details

Ramon Klein Geltink

Assistant Professor

The University of British Columbia

CANADA
View details

David E Sanin

Assistant Professor

Johns Hopkins University

UNITED STATES
View details

Jan-Wilm Lackmann

Head of Proteomics Facility

University of Cologne

GERMANY
View details